Increased autophagy in ephrinB2 deficient osteocytes is associated with hypermineralized, brittle bones

Christina Vrahnas^{1,2}, Toby A Dite^{2,3}, Niloufar Ansari^{1,2}, Blessing Crimeen-Irwin¹, Huynh Nguyen⁴, Mark R Forwood⁴, Yifang Hu⁵, Mika Ikegame⁶, Keith R Bambery⁷, Cyril Petibois⁸, Mark J Tobin⁷, Gordon K Smyth^{5,9}, Jonathan S Oakhill^{2,3,10}, T John Martin^{1,2} & Natalie A Sims^{1,2,11*}

¹Bone Biology and Disease Unit, St. Vincent's Institute of Medical Research, Melbourne, Victoria, 3065, Australia

²Department of Medicine, The University of Melbourne, St. Vincent's Hospital, Melbourne, Victoria, 3065, Australia

³Metabolic Signalling Laboratory, St. Vincent's Institute of Medical Research, Melbourne, Victoria, 3065, Australia

⁴School of Medical Science and Menzies Health Institute Queensland, Griffith University, Gold Coast, 4222, Queensland, Australia

⁵Bioinformatics Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, 3010, Australia

⁶Department of Oral Morphology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, 700-8525, Japan

⁷Infrared Microspectroscopy (IRM) Beamline, Australian Synchrotron, Clayton, Victoria, 3168, Australia

⁸University of Bordeaux, Inserm U1029 LAMC, Allée Geoffroy Saint-Hilaire Bat. B2, F33600, Pessac, France

⁹School of Mathematics and Statistics, The University of Melbourne, Melbourne, Victoria, 3010, Australia

¹⁰Mary MacKillop Institute for Health Research, Australian Catholic University, Victoria, 3065, Australia

¹¹Lead contact

Keywords: Osteocytes, PTH, mineralisation, FTIR, autophagy

*Correspondence: nsims@svi.edu.au

Summary

Mineralized bone forms when collagen-containing osteoid accrues hydroxyapatite crystals. This process has two phases: a rapid initiation (primary mineralization), followed by slower accrual of mineral (secondary mineralization) that continues until that portion of bone is renewed by remodelling. Within the bone matrix is an interconnected network of cells termed osteocytes. These cells are derived from bone-forming osteoblasts. Osteoblast differentiation requires expression of ephrinB2, and we were intrigued about why ephrinB2 continues to be expressed in mature osteocytes. To determine its function in osteocytes, we developed an osteocyte-specific ephrinB2 null mouse and found they exhibited a brittle bone phenotype. This was not caused by a change in bone mass, but by an intrinsic defect in the strength of the bone material. Although the initiation of osteoid mineralization occurred at a normal rate, the process of secondary mineralization was accelerated in these mice. The maturing mineralized bone matrix incorporated mineral and carbonate more rapidly than controls, indicating that osteocytic ephrinB2 suppresses mineral accumulation in bone. No known regulators of mineralization were modified in the bone of these mice. However, RNA sequencing showed differential expression of a group of autophagy-associated genes, and increased autophagic flux was confirmed in ephrinB2 knockdown osteocytes. This indicates that the process of secondary mineralization in bone makes use of autophagic machinery in a manner that is limited by ephrinB2 in osteocytes, and that this process may be disrupted in conditions of bone fragility.

Introduction

The skeleton is unique in the human body because its organic structure is hardened by integration of mineral, allowing it to provide support for locomotion and protection for internal organs. This mineralized bone forms when collagencontaining osteoid, deposited by osteoblasts, accrues hydroxyapatite crystals. The process has two phases: a rapid initiation (primary mineralization), followed by slower accrual of mineral (secondary mineralization) that continues until that portion of bone is renewed by remodelling. During bone formation, osteoblasts become incorporated in the non-mineralized osteoid and differentiate into osteocytes to form a highly connected network of specialized cells residing within the mineralized matrix^{1,2}. In response to stimuli such as mechanical load, hormones, and cytokines, osteocytes release proteins that both stimulate³ and inhibit⁴ bone forming osteoblasts. Both osteoblasts and osteocytes express proteins that initiate mineralization of the osteoid matrix ⁴⁻⁷, but it is not known how the speed of continuing mineral deposition is controlled.

Two related agents that stimulate bone formation are the agonists of the parathyroid hormone (PTH) receptor (PTHR1): PTH, and PTH-related protein (PTHrP). Locally-derived PTHrP, from osteoblasts and osteocytes stimulates bone formation in a paracrine manner ^{8,9}, and this action has been exploited by the pharmacological agents teriparatide and abaloparatide. These are the only

pharmacological agents that are currently available clinically that can increase bone mass in patients with fragility fractures ^{10,11}. Both PTH and PTHrP treatment substantially increase the expression of the contact-dependent signalling molecule ephrinB2 in osteoblasts *in vitro* and in bone *in vivo* ¹². We have previously shown that the interaction of ephrinB2 (gene name: *Efnb2*) with its receptor, EphB4, provides a checkpoint through which osteoblasts must pass to reach late stages of osteoblast and osteocyte differentiation ¹³⁻¹⁶. Furthermore, osteoblast-specific deletion of ephrinB2 compromised bone strength by impairing osteoblast differentiation, and delaying the initiation of bone mineralization, ultimately leading to a mild osteomalacia (high osteoid content)¹⁴. This indicated that osteoid mineralization is initiated by osteoblasts after the ephrinB2:EphB4 differentiation checkpoint.

We were intrigued that ephrinB2 expression remains high in fully embedded osteocytes ¹², beyond the differentiation checkpoint. Given the extensively connected nature of osteocytes and the contact-dependent nature of ephrinB2:EphB4 signalling, we hypothesized that ephrinB2 regulates the function of osteocytes embedded in the bone matrix. We undertook the present work to determine the requirement for ephrinB2 expression in osteocytes. We find that ephrinB2 in osteocytes does not regulate the initiation of mineralization, but is required to limit secondary mineral accrual and retain the flexibility of the bone matrix. We also show that, in the absence of ephrinB2, osteocytes exhibit modified

4

levels of genes associated with autophagy and increased autophagic flux, providing evidence that autophagic processes in osteocytes directly control mineralization.

Results

EphrinB2 is upregulated by PTH and PTHrP in Ocy454 cells.

Upregulation *Efnb2* in osteocytes by PTH and PTHrP stimulation was confirmed in Ocy454 cells (Fig. 1A); PTH(1-34) and PTHrP(1-141) both significantly increased *Efnb2* mRNA levels. shRNA knockdown of PTHrP (*Pthlh*) in Ocy454 cells resulted in significantly lower *Efnb2* mRNA levels at all timepoints, compared to vector control (Fig. 1B), indicating that endogenous PTHrP expression by osteocytes is required for normal *Efnb2* expression in osteocytes.

Deletion of ephrinB2 in osteocytes results in a brittle bone phenotype

FACS purification of DMP1-GFP+ osteocytes and use of primers targeted to the exon 1-2 boundary of *Efnb2* confirmed that *Efnb2* mRNA was present in osteocytes of control mice. Analysis of GFP+ cells confirmed effective targeting of *Efnb2* in osteocytes from *Dmp1Cre.Efnb2^{f/f}* mice, while retaining *Efnb2* in non-osteocytic cells (Fig. 1C).

Three-point bending tests demonstrated a strength defect in female $Dmp1Cre.Efnb2^{f/f}$ femora compared to $Dmp1Cre.Efnb2^{w/w}$ controls (Fig. 2A-F, Table 1). There was no significant difference in bone strength observed in males (Supplementary Table 1). A significantly higher percentage of bones from $Dmp1Cre.Efnb2^{f/f}$ mice fractured at lower deformation than controls (Fig. 2B).

Average load-deformation curves also showed this (Fig. 2A), and indicated that femora from *Dmp1Cre.Efnb2^{f/f}* mice could withstand less force before yielding (Table 1) and before breaking (ultimate force, Fig. 2C), and deformed less at the maximum force that bones could withstand, compared to controls (Fig. 2D). The reduction in ultimate deformation was largely due to a deficit in the extent of deformation from the yield point onwards (Fig. 2E, Table 1). Energy absorbed to failure was also significantly lower in *Dmp1Cre.Efnb2^{f/f}* mice compared to controls (Fig. 2F). Stiffness (the slope of the load / deformation curve before the yield point) was not significantly modified (Table 1). Instead, *Dmp1Cre.Efnb2^{f/f}* femora had a lower yield point, and once they began to yield, they withstood less force and deformed less than controls.

The reduction in bone strength in $Dmp1Cre.Efnb2^{f/f}$ mice was not associated with any significant difference in moment of inertia (Fig. 3A) or dimensions of the cortical bone (Table 1). Indeed, when normalised for cortical dimensions, femora from $Dmp1Cre.Efnb2^{f/f}$ mice showed impaired material strength compared to controls (Fig. 3B), including lower yield stress and strain (Table 1), lower ultimate stress (Fig. 3C), lower ultimate strain (Fig. 3D), and lower toughness (Fig. 3E). Elastic modulus was not significantly altered (Table 1), consistent with the normal stiffness data obtained. Reference point indentation also indicated a change in material strength independent of geometry, with a significantly greater indentation distance increase (IDI) (the increase in the test probe's indentation distance in the last cycle relative to the first cycle) in $Dmp1Cre.Efnb2^{f/f}$ bones compared to controls (Fig. 3F). No other parameters measured by RPI were significantly altered (Supplementary Table 2).

This indicates that *Dmp1Cre.Efnb2*^{f/f} bones are more brittle than controls due to a defect in bone material compisition.

Bone formation rate is unchanged, but osteocyte density is greater in Dmp1Cre.Efnb2^{f/f} bones

In contrast to $OsxCre.Efnb2^{f/f}$ mice (with ephrinB2 deleted in osteoblasts) which exhibited reduced mineral appositional rate at the periosteum ¹⁴, $Dmp1Cre.Efnb2^{f/f}$ mice exhibited no significant change in periosteal mineral appositional rate (Table 1) or periosteal mineralising surface (Table 1). We also assessed trabecular bone, which was of normal volume (Supplementary Table 3), and detected no significant difference in trabecular bone formation rate, mineral appositional rate, or mineralising surface (Table 2). There were also no differences detected in osteoid thickness, osteoid surface, osteoblast surface or osteoclast surface in $Dmp1Cre.Efnb2^{f/f}$ bones compared to controls (Table 2). This indicated that osteoblast-mediated osteoid deposition and the initiation of bone mineralization occurred at a normal rate in $Dmp1Cre.Efnb2^{f/f}$ bones.

Backscattered electron microscopy detected no change in osteocyte lacunar size in the femoral midshaft of *Dmp1Cre.Efnb2^{f/f}* mice, however osteocyte lacunar density was significantly greater compared to controls (Table 3). This suggests a greater rate of osteocyte incorporation into the bone matrix during osteoid deposition.

Dmp1Cre.Efnb2^{f/f} bone has greater mineral and carbonate deposition

Since material strength was impaired and the (blinded) technician cutting the sections for histomorphometry noted that some samples were very difficult to cut, we assessed bone material by a number of methods. We detected no difference in the proportion of woven to lamellar cortical bone by polarised light microscopy (Table 3) and no significant alteration in cortical tissue mineral density (Table 1) in *Dmp1Cre.Efnb2^{f/f}* femora compared to controls. We then used sFTIRM to measure bone composition at the periosteum, a region lacking bone remodelling, thereby allowing assessment of the bone matrix as mineralization progresses ¹⁷. Three regions of increasing matrix maturity were measured (Fig. 4A). Average spectra for each genotype, taken from the intermediate region indicated altered spectral geometry in *Dmp1Cre.Efnb2^{f/f}* bone compared to controls (Fig. 4B). *Dmp1Cre.Efnb2^{f/f}* bone had higher phosphate and carbonate peaks indicating a greater level of mineralization. In addition, *Dmp1Cre.Efnb2^{f/f}* bone showed a lower amide I, but higher amide II peak, suggesting greater compaction of collagen in *Dmp1Cre.Efnb2*^{f/f} mice.

When quantified, control bones showed the changes associated with bone matrix maturation previously reported on murine periosteum: with increasing depth from the bone edge, mineral:matrix ratio increased while amide I:II ratio decreases ¹⁷ (Fig. 4C-E). The process of mineral accrual was accelerated in *Dmp1Cre.Efnb2*^{f/f} bone (Fig. 4C,D): in the two most immature regions of bone, mineral:matrix ratio was

significantly greater in *Dmp1Cre.Efnb2^{[//}* bone compared to control (Fig. 5C) and amide I:II ratio was significantly lower (Fig. 5E). In addition, although carbonate:mineral ratio did not increase significantly with maturation in the control mice, there carbonate:mineral ratio increased with increasing matrix maturity in the *Dmp1Cre.Efnb2^{[//}* bone and reached a higher level of carbonate:mineral ratio than controls in the two more mature regions (Fig. 5E). The increase in mineral:matrix ratio was not due to a lower bone collagen content; hydroxyproline levels were significantly higher in whole bone samples from *Dmp1Cre.Efnb2^{[//}* bone compared to control (Table 3). Collagen crosslinking did not change with bone maturity, but was significantly greater in the intermediate region of *Dmp1Cre.Efnb2^{[//}* bones (Fig. 4F) indicating that crosslinks mature in the same region in which mineral and carbonate accumulate. The *Dmp1Cre.Efnb2^{[//}* brittle bone phenotype is therefore associated with more rapid bone matrix maturation, including rapid accumulation of mineral and carbonate substitution and more rapid collagen compaction within the matrix.

Since the amide I:II ratio has not yet been validated in bone as an indicator of collagen orientation, we used pFTIRI in the same region to visualise and quantitate the spatial variation of collagen fibres (Fig. 5A,B,D,E). The 0° and 90° polarising filters were used to preferentially enhance the signal from molecular bonds oriented parallel and perpendicular, respectively, to the bone tissue section surface ¹⁸. We noted three "zones" within the cortical bone in control tibiae, where the pFTIRI 0° polarising filter indicated higher amide I:II ratio on both periosteal and endocortical regions compared to central cortical bone (Fig. 5A,C). *Dmp1Cre.Efnb2f*/f bones

showed a greater amide 1:11 ratio in the endocortical region compared to periosteal and central cortical bone (Fig. 5B,C). When quantified, the pFTIRI 0° polarising filter result validated the sFTIRM observations, and confirmed a significantly lower amide 1:11 ratio in the periosteal region in *Dmp1Cre.Efnb2^{III}* bone compared to control (Fig. 5C). In *Dmp1Cre.Efnb2^{III}* mice, the difference in amide 1:11 ratio between periosteal and central cortical regions was no longer detected, with both showing significantly lower amide 1:11 ratio than the endocortical region (Fig. 5B,C). When quantiated under the 90° polarising filter, the amide 1:11 ratio was significantly lower in control bone at intracortical and endocortical regions due to greater amide 11 signal (Fig. 5D, F). A similar observation was made in *Dmp1Cre.Efnb2^{III}* mice with the 90° polarising filter (Fig. 5E,F) and no difference was observed in fibres aligned under this filter between genotypes (Fig. 5F). This analysis validated the sFT1RM observations, and confirmed a significantly lower amide 1:11 ratio in *Dmp1Cre.Efnb2^{III}* bone compared to control.

EphrinB2 deficiency in osteocytes leads to dysregulation of autophagy-related genes and increased autophagy

To identify mechanisms by which ephrinB2-deficiency alters mineral and matrix composition leading to fragile bones, RNA sequencing was performed on marrow-flushed femora from 12-week old *Dmp1Cre.Efnb2f/f* and control mice. This revealed 782 up-regulated genes and 1024 down-regulated genes (FDR < 0.05). In the full list of differentially expressed genes, known osteocyte-specific and mineralization genes were not present (e.g. *Dmp1, Mepe, Sost, Phospho1, Enpp1, Enpp2, Fgf23*). Fig. 6A,B 10

shows the top 30 differentially expressed genes; none have previously been associated with osteocyte function, bone mineralisation, or ephrinB2 function. We noted that a third of the top genes are associated with the process of autophagy. Six were upregulated in the ephrinB2-deficient bone: *Fam134b* ¹⁹, *Fbxo32* ^{20,21}, *Lama2* ²², *Bnip3* ^{23,24}, *Trim63* ²⁵ and *Peg3* ²⁶. The other four were downregulated: *Eps8l1*²⁷, *Klf1* ²⁸ and *Tspo2*²⁹ and *Unc5a* ³⁰.

To identify whether suppression of ephrinB2 in osteocytes leads to increased autophagy in an independent cell-specific model, we generated *Efnb2* deficient Ocy454 osteocytes and assessed autophagy levels. Stable *Efnb2* knockdown was confirmed in mature Ocy454 cells at days 11 and 14 (Fig. 6C). The rate of autophagy was measured by assessing LC3-II:I ratio after treatment with the autophagic flux inhibitor chloroquine (CQ) to allow measurement of autophagosome formation³¹. CQ treatment caused a significant elevation in LC3-II:I ratio in both vector and *Efnb2* knockdown cells, as anticipated. This effect was amplified in *Efnb2* shRNA knockdown cells, shown by the increased fold change of CQ-treated *Efnb2* knockdown cells compared to untreated cells. This indicated that ephrinB2-deficient osteocytes have greater susceptibility to autophagy than vector control (Fig. 6D).

Discussion

This work demonstrates that bone flexibility is maintained and mineral accrual limited by ephrinB2 signalling in osteocytes. In the absence of ephrinB2, autophagic processes are increased, and although the initiation of osteoid mineralization occurs at a normal rate, as soon as the process commences, mineral deposition and maturation is accelerated, resulting in a brittle bone phenotype. This indicates that the control mechanisms for primary and secondary mineralization are different, and that osteocytes within the bone matrix control the progress of secondary mineralization. This has major implications for understanding how osteocytes contribute to bone strength.

Bone strength is controlled by both bone mass, and the composition of the bone matrix itself. Bone mass is determined by the balance between the activities of bone-forming osteoblasts and bone-resorbing osteoclasts. Bone compositional strength is determined by the content and orientation of collagen, as well as the content and nature of mineral crystals within that collagen network. Previously it has been noted that major defects in bone compositional strength can result from defective collagen deposition (as in osteogenesis imperfecta) or delayed initiation of mineralisation (as in osteogenesis imperfecta) or delayed initiation of mineralisation (as in osteomalacia or rickets). In this study, we report a third possible cause of bone fragility: accelerated maturation of the mineralized bone matrix (Fig. 7). In brittle *Dmp1Cre.Efnb2*^{f/f} bones, mineral:matrix ratio in the first region of mineral deposition was higher than controls. Since there was no difference in the rate at which osteoid mineralization was initiated (MAR), this suggested that

mineralization commenced rapidly as soon as it was initiated: essentially, mineral is "dumped" into the matrix. The normal gradual increase in mineral:matrix ratio, previously described in murine, rabbit, rat, baboon and human cortical bone ^{17,32-36}, is accelerated in the absence of ephrinB2.

This was not the only aspect of mineral accumulation that was modified. Bone mineral crystals are a modified hydroxyapatite comprised of calcium, phosphate and hydroxyl ions which can be replaced by fluoride, chloride or carbonate. As hydroxyapatite matures in bone, carbonate:mineral ratio increases due to carbonate substitution for phosphate or hydroxyl ions ^{17,37-40}. *Dmp1Cre.Efnb2f/f* bones also showed a more rapid increase in carbonate incorporation within the bone matrix. Both mineral accrual and carbonate substitution within the mineral occur at an accelerated rate in the absence of ephrinB2.

A third aspect of bone matrix maturation was accelerated in *Dmp1Cre.Efnb2f/f* bones: the reduction in the amide I:II ratio. Amide I:II ratio represents peptide bond vibrations within the collagen molecule ⁴¹. Amide I (C=O stretch) and amide II (C-N, N-H bend) molecular vibrations exhibit dichroism perpendicular (*z*-axis direction) and parallel (*x*-axis) to the collagen molecular triple helix axis, respectively ⁴². We have previously reported that amide I:II ratio declines with increasing mineral accumulation in control mice, likely as a result of more compaction (or steric hindrance) of the collagen molecule in the perpendicular direction as mineral accumulates ¹⁷. The early lowering of the amide I:II ratio in *Dmp1Cre.Efnb2*^{I/f} bone indicates a greater rate of collagen compaction as mineral accumulates in the

matrix. This process is exaggerated in *Dmp1Cre.Efnb2^{f/f}* mice. Use of the 0° polarising filter suggests that increase in collagen compaction is specific to those collagen fibres aligned longitudinally to the bone section. This suggests that these fibres may be more important for absorbing mechanical forces along the length of the tibiae and their altered organization may also contribute to the bone brittleness in ephrinB2-deficient mice.

Another aspect of bone matrix maturation that was accelerated was the incorporation of osteocytes into the bone matrix: $Dmp1Cre.Efnb2^{f/f}$ mice exhibited a greater osteocyte density. As osteoid is deposited, a subset of osteoblasts become incorporated into the bone matrix: these are the cells that differentiate into osteocytes. Our data suggests that these pre-osteocytes are incorporated into the bone matrix at a faster rate in $Dmp1Cre.Efnb2^{f/f}$ bone. Dmp1Cre targets late osteoblasts at the stage where they become embedded within the newly formed osteoid ^{43,44}; the greater density of osteocytes incorporated may promote mineral accumulation and carbonate incorporation in $Dmp1Cre.Efnb2^{f/f}$ bones.

Though this is the first report of a low amide I:II ratio being associated with bone fragility, the cause of the brittle phenotype is likely to be the combination of reduced amide I:II, and increased mineral:matrix and carbonate:mineral. The association of high carbonate with increased bone fragility is consistent with earlier work describing a higher carbonate:mineral ratio in bone specimens from women with postmenopausal osteoporosis ⁴⁵ or with greater fracture susceptibility ⁴⁶. High mineral:matrix ratio has also been reported in other examples of bone brittleness,

such as patients with atypical femoral fracture ⁴⁷, and murine models of osteogenesis imperfecta^{48,49}. In the latter cases it is accompanied by defects in collagen or cartilage content and defects in osteoblast function, but the present model exhibited no change in osteoblast function.

A comparison of this mouse model with our earlier model lacking ephrinB2 throughout the osteoblast lineage provides new information about the specific stages of osteoblast/osteocyte differentiation and their roles in the process of bone mineralization. Our earlier model lacking ephrinB2 throughout the osteoblast lineage ($OsxCre.Efnb2^{f/f}$) did not exhibit a brittle bone phenotype, but had bones that were more elastic due to delayed initiation of primary mineralization ¹⁴. This indicated that the stage of osteoblast differentiation that initiates primary mineralization is beyond the ephrinB2:EphB4 osteoblast differentiation checkpoint. In *Dmp1Cre.Efnb2^{f/f}* mice, osteoblasts would survive past the checkpoint at which anti-apoptotic action of ephrinB2 is required; this has allowed us to define an action for EphrinB2 later in osteoblast differentiation. Normal initiation of mineralization in *Dmp1Cre.Efnb2^{f/f}* bone indicates that the stage of osteoblast differentiation that controls this process is not only after the ephrinB2:EphB4 checkpoint, but before the stage of *Dmp1Cre* expression. The stage of osteoblast/osteocyte differentiation after *Dmp1* is expressed does not control initiation of mineralisation but controls the rate at which mineral accumulates (Fig. 7). Since PTH and PTHrP promote ephrinB2 expression in both osteoblasts¹² and osteocytes, they may promote both the initiation of osteoid mineralization and restrain the rate of mineral accrual.

While there is not evidence for altered mineral accrual with pharmacological administration of PTH, the reduced material strength of mice with PTHrP deletion targeted to osteocytes provides support for a role of PTHrP in regulating mineral accrual via ephrinB2-dependent actions in the osteocyte ⁵⁰.

The processes that control the rate of mineral accumulation in bone are poorly defined and our data suggests that autophagic processes in the osteocyte that are inhibited by ephrinB2 limit this process. Unbiased RNA sequencing detected no changes in mRNA levels of genes known to regulate the initiation of mineralization (*Dmp1* and *Mepe*). Instead, it identified dysregulation of a range of autophagyassociated genes and we confirmed that ephrinB2 inhibits autophagy in vitro. Autophagy is a lysosome-based pathway that contributes to diverse cellular functions, such as adaptation to starvation, quality control of intracellular processes, protein secretion, and elimination of intracellular microbes ⁵¹⁻⁵³. While explorations of the role of autophagy in osteocytes is in its infancy, previous work has demonstrated that autophagy increases during osteoblast differentiation ⁵⁴, and that mice with osteoblast-lineage or osteocytic deletion of either *Atg5* or *Atg7* have reduced autophagy and reduced osteoblast numbers ⁵⁴⁻⁵⁶. In our *Dmp1Cre.Efnb2^{f/f}* model osteoblast numbers were not altered, and we observed no changes in *Atg5* or *Atg7*, suggesting a subset of autophagic processes that control mineral maturation without controlling osteoblast differentiation are modified in the absence of ephrinB2.

We suggest two ways by which increased autophagic flux may cause the brittle bone phenotype: (1) controlling osteocyte differentiation and adaptation to the mineralized environment, and (2) contributing to mineral secretion. After osteocytes are embedded in osteoid, they develop dendritic extensions and adjust to a more hypoxic environment ⁵⁷. Autophagic processes may contribute to this transition by allowing the osteocyte to break down complex molecules to use for energy ⁵⁸, promoting faster organelle recycling, and preservation of nutrients. Mineralization involves the release of cell-derived extracellular membrane-enclosed particles of poorly crystalline mineral, termed matrix vesicles ^{59,60} and subsequent nucleation (ordered crystal formation) of that amorphous mineral by heterogeneous nucleation driven by contact with collagen, and by secretion of competent apatite nucleators ⁶¹⁻⁶³. Nollet *et. al* suggested that autophagic vacuoles could serve as vehicles for osteoblasts to secrete apatite crystals in the extracellular space via exocytotic processes ⁵⁴; we propose that osteocytes may also release mineral through this process. Direct release of mineral by osteocytes has been noted both during remineralization of osteocyte lacunae after lactation ⁶⁴ and in egg-laying hens ⁶⁵. Our data suggest that the secretion of both vesicles and nucleators by osteocytes promotes mineral accrual during physiological bone formation. We suggest that ephrinB2-deficient osteocytes use autophagic machinery to release more matrix vesicles and apatite nucleators, thereby driving an increase in bone mineral, resulting in brittle bone matrix.

These findings have implications for other organ systems. EphrinB2 in odontoblasts, which are closely related cells to osteoblasts and osteocytes ^{66,67} may also control mineralisation in teeth. Pathological mineralisation, such as that in heterotopic ossification after trauma ⁶⁸, vascular or renal calcification ^{69,70} may also involve autophagy and be limited by ephrinB2, since it is also expressed in those tissues.

In conclusion, ephrinB2 is required to restrain autophagy in the osteocyte, and to prevent the formation of brittle bone. Osteocytic ephrinB2 limits the accumulation of mineral and carbonate substitution within the hydroxyapatite matrix and restrains collagen fibre compaction. This indicates a mechanism by which bone strength is regulated independently of bone size, and independently of osteoblast and osteoclast activities.

Experimental Procedures

Cell culture

Ocy454 cells were cultured as previously described, in α MEM supplemented with 10% FBS and 1% Penicillin-Streptomycin-Amphotericin B and Glutamax ⁷¹. Cells were maintained in permissive conditions (33°C) and differentiated to osteocytes at 37 °C ⁷¹. For 2D cell cultures, Ocy454 cells were plated at 2.5 x 10⁵ cells per well in six-well plates. Three-dimensional (3D) culture was performed using Reinnervate ® Alvetex scaffold 6-well inserts (Pittsburgh, PA, USA) made of highly porous, cross-linked polystyrene discs with 200 µm thickness and 22mm diameter. The Alvetex inserts were prepared for seeding by a 70% ethanol wash, followed by two washes with complete culture media. Cells were seeded at 1.6 x 10⁶ cells per insert. Cells were grown at the permissive temperature (33°C) for 3 days prior to transferring to (37°C) for differentiation.

To study how *Efnb2* mRNA is regulated by PTH and PTHrP, Ocy454 cells at day 14 of differentiation were serum starved overnight in αMEM supplemented with 1% FBS and 1% PSA and Glutamax. Cells were then treated with Human PTH(1-34) (10 nM) or Human PTHrP(1-141) (10 nM) for 6 hours. After 6 hours, cells were washed with phosphate buffered saline (PBS) and RNA samples were collected as described below.

Pthlh knockdown

shRNA with sequence 5'CCG-GCC-AAT-TAT-TCC-TGT-CAC-TGT-TCT-CGA-GAA-CAG-TGA-CAG-GAA-TAA-TTG-GTT-TTT-TG-3'was used to knock down *Pthlh* in Ocy454 19 cells as previously reported ⁹. Undifferentiated Ocy454 cells were infected with virus and selected with puromycin (5 ug/ml), then cultured at permissive temperature (33°C) before transfer to 37°C for differentiation. Cells were assessed by quantitative real-time PCR (qRT-PCR) at day 0 (undifferentiated), 7 and 14 (differentiated) ⁹.

qRT-PCR analysis

RNA was extracted by RNA extraction kits with on-column DNase digestion (Qiagen, Limburg, Netherlands; Bioline, London, UK), or TriSure reagent (Bioline, London, UK). Extracted RNA was DNase treated with Ambion TURBO DNA-free kit (Life Technologies) and quantified on a NanoDrop ND1000 Spectrophotometer (Thermo Scientific, Wilmington, DE, USA). cDNA was synthesised from total RNA with AffinityScript cDNA synthesis kits (Agilent Technologies, Santa Clara, CA, USA). Gene expression for PTH and PTHrP treated Ocy454 cells were quantified on a Stratagene Mx3000P QPCR system (Agilent) with SYBR Select Master Mix (Applied Biosystems) with primers specific to *Efnb2*; forward 5'-GTGCCAGACAAGAGCCATGAA-3' and reverse 5'-GGTGCTAGAACCTGGATTTGG-3' ¹². Gene expression *for Pthlh* knockdown cells was analysed using the Multiplex SensiMix II Probe kits (Bioline, London, UK) with primers specific to *Efnb2*, as previously described ¹³. Gene expression levels between samples was normalized to hypoxanthine phosphoribosyltransferase 1 (Hprt1) expression. Relative expression was quantified using the comparative CT method (2-(Gene Ct - Normalizer Ct)).

Mice

Dmp1Cre mice (Tg(Dmp1-Cre)^{1Jqfe}) (containing the DMP1 10-kb promoter region) were obtained from Lynda Bonewald (University of Kansas, Kansas City, KS, USA)⁴³ and ephrinB2-floxed (Efnb2^{tm1And}) mice were obtained from David J. Anderson (Howard Hughes Medical Institute, California Institute of Technology, Pasadena, CA, USA) ⁷²; all mice were backcrossed onto C57BL/6 background. Mice hemizygous for Dmp1Cre were crossed with Efnb2^{f/f} mice to generate Dmp1Cre.Efnb2^{f/w} breeders, which were used to generate Dmp1Cre.Efnb2^{f/f} mice and Dmp1Cre.Efnb2^{w/w} littermates or cousins, which were used as controls for all experiments. To generate GFP+ osteocytes, these mice were crossed with Dmp1-GFP (Tg(Dmp1-Topaz)^{11kal} mice obtained from Dr Ivo Kalajzic, University of Connecticut Health Science Center, via the colony of Dr Hong Zhou, ANZAC Research Institute, Sydney ⁷³. For all tissue collections, mice were fasted for 12 hours prior to anaesthesia with ketamine and blood was collected via cardiac puncture, as previously described ⁷⁴. Both male and female mice were analysed. All animal procedures were conducted with approval from the St. Vincent's Health Melbourne Animal Ethics Committee.

Confirmation of Efnb2 mRNA targeting in osteocytes

To confirm specific targeting of *Efnb2* mRNA in osteocytes, *Dmp1Cre.Efnb2^{f/f}* mice were crossed with *Dmp1-GFP* mice to allow purification of osteocytes by fluorescence-activated cell sorting (FACS), according to our previously published

methods 9,75. Osteocytes from 6-week old Dmp1Cre.Dmp1-GFP-Tg.Efnb2^{w/w} and *Dmp1Cre.Dmp1-GFP-Tg.Efnb2^{f/f}* mice were isolated from marrow-flushed long bones by seven sequential 15-minute digestions in 2 mg/ml dispase (Gibco, Grand Island, NY, USA) and 1 mg/ml collagenase type II (Worthington, Lakewood, NJ, USA). Fractions 2–7 were collected, pooled, and resuspended in alpha modified Eagle's medium (α -MEM; Gibco, Grand Island, NY, USA) containing 10% FBS and centrifuged. Pellets were resuspended in FACS buffer before cell sorting. Prior to sorting, dead cells and debris were removed based on side scatter (SSC) area and forward scatter (FSC) area, and doublets were excluded based both on SSC width (W) vs SSC height (H) and on FSC-W vs FSC-H. Cells were sorted with excitation 488 nm and 530/30 or 530/40-emission filter for GFP on a BD FACS Influx cell sorter (BD Biosciences, Scoresby, Australia). RNA was extracted using Isolate II Micro RNA kit (Bioline, London, UK). cDNA was prepared using a Superscript III kit (Thermo Fisher, Scoresby, Australia). *Efnb2* primers directed to the targeted region were: forward 5'-AGAACTGGGAGCGGCTTG-3', reverse 5'-TGGCCAACAGTTTTAGAGTCC- $3'^{14}$. Gene expression levels between samples were normalised to Beta-2 microglobulin ($\beta 2m$): forward 5'- TTC ACC CCC ACT GAG ACT GAT-3', reverse 5'-GTC TTG GGC TCG GCC ATA-3' and hydroxymethylbilane synthase (*Hmbs*): forward 5'-TCATGTCCGGTAACGGCG-3', 5'-CACTCGAATCACCCTCATCTTTG-3'reverse expression. Relative expression was quantified using the comparative threshold cycle (Ct) method (2 - (Gene Ct - Normalizer Ct)).

3-point bending and Reference Point Indentation (RPI)

Structural and material properties were analysed in femora from male and female 12-week-old mice by 3-point bending, as described previously ⁷⁴. Cortical dimensions including anteroposterior (AP) and mediolateral (ML) widths were measured at the cortical midshaft by microCT. Moment of inertia was calculated based on AP, ML and cortical thickness, as previously described ⁹. Load was applied in the anterior-posterior direction of the femoral mid-shaft between two supports that were 6.0mm apart. Load-displacement curves were recorded at a crosshead speed of 1.0 mm/s using an Instron 5564A dual column material testing system, and Bluehill 2 software (Instron, Norwood, MA, USA). Ultimate force (N), ultimate deformation (mm), post-yield deformation (mm) and energy absorbed to failure (m]) were measured from the load-displacement curves. Combining the geometric calculations and the biomechanical test results, the material properties of each bone were calculated as previously described ⁷⁴ to obtain ultimate stress (MPa), ultimate strain (%) and toughness (J/mm³).

Local bone material properties were examined by reference point indentation (RPI) using a BP2 probe assembly apparatus (Biodent Hfc; Active Life Scientific Inc., Santa Barbara, CA, USA), as previously described ⁷⁴. Briefly, measurements were taken at the femoral mid-shaft, 6 mm from the base of the femoral condyles for consistent probe positioning between samples. A maximum indentation force of 2N was achieved by manually applying a 300g reference force to femora. 5 measurements were taken per sample using a 2N, 10-cycle indentation protocol at 2N force. Pre-and post-experiment measurements were taken on a polymerized methyl 23

methacrylate block to ensure that probe assembly was not affected during testing. The indentation distance increase (IDI) was measured as the indentation distance in the last cycle relative to the first cycle ⁷⁶.

Histomorphometry, back scatter electron microscopy (BSEM) and Micro-Computed Tomography (microCT)

Tibiae from 12-week-old female mice were fixed in 4% paraformaldehyde, embedded in methyl methacrylate (MMA), sectioned longitudinally and stained as described previously ¹³. Calcein was administered by intraperitoneal (IP) injection 7 and 2 days before tissue collection. Periosteal parameters were measured on the medial side of the tibial mid-shaft (1500 µm from the base of the growth plate), as previously described ⁷⁷. Trabecular parameters were measured in the secondary spongiosa, commencing 370 µm below the growth plate, in a 1110 µm² region in the proximal tibia, as previously described ⁷⁷ (Osteomeasure; Osteometrics, Atlanta, GA, USA).

Polarized light microscopy and BSEM were performed on 100 µm thick transverse sections from the femoral mid-shaft generated using an Isomet Saw (Buehler, Lake Bluff, IL, USA); measurements included the entire bone interface. Irregular fibre orientation was measured as woven bone and well-aligned fibre orientation was measured as previously described ⁷⁴.

BSEM was used to acquire gray-level images of mineralized cortical bone to identify osteocyte lacunae. Osteocyte lacunae were imaged on both anterior and posterior

24

sides of the femur at 500x magnification (approximately 600 μm in length) using an FEI Quanta FEG 200 solid state backscattered scanning electron microscope. Imaging was performed at low vacuum using water at a 9.8mm working distance. Lacunae were quantified using MetaMorph (v7.8.3.0; Molecular Devices; Sunnyvale, CA, USA) by establishing an inclusive threshold for dark objects to distinguish bone from background. Integrated Morphometry Analysis (IMA) was applied with a 2.43 - 24.31 μm² filter for lacunae area, to exclude cracks and blood vessels. The thresholded bone area was combined with total lacunar area to calculate the total bone area. Parameters measured included osteocyte lacunar size, size of the largest 20% of osteocyte lacunae and osteocyte lacunar density.

MicroCT was performed on femora using the SkyScan 1076 system (BrukermicroCT, Kontich, Belgium). Images were acquired using the following settings: 9µm voxel resolution, 0.5mm aluminium filter, 50 kV voltage, and 100 µA current, 2600 ms exposure time, rotation 0.5 degrees, frame averaging =1. Images were reconstructed and analysed using NRecon (version 1.6.9.8), Dataviewer (version 1.4.4) and CT Analyser (version 1.11.8.0). Femoral trabecular analysis region of interest (ROI) was determined by identifying the distal end of the femur and calculating 10% of the total femur length towards the mid-shaft, where an ROI of 15% of the total femur length was analysed. Bone structure was measured using adaptive thresholding (mean of min and max values) in CT Analyser. Cortical analyses were performed in a region of 15% of the femoral length commencing from 30% proximal to the distal end of the femur and extending toward the femoral midshaft. The lower thresholds used for trabecular and cortical analysis were equivalent to 0.20g/mm³ and 0.642g/mm³ calcium hydroxyapatite (CaHA), respectively. Cortical tissue mineral density (Ct.TMD) was analysed in the same cortical region of interest, as described above. TMD calibration was performed using two phantom rods with concentrations of CaHA of 0.25 and 0.75g/cm⁻³, scanned under the same conditions and settings as the samples.

Synchrotron-based Fourier Transform Infrared Microspectroscopy (sFTIRM) and polarized light FTIR Imaging (pFTIRI)

sFTIRM was used to examine bone composition at the cortical diaphysis in 3µm longitudinal sections of methyl methacrylate (MMA)-embedded tibiae. Sections were imaged using a Bruker Hyperion 2000 IR microscope coupled to a V80v FTIR spectrometer located at the IR Microspectroscopy beamline at the Australian Synchrotron, as previously described ¹⁷. Sections were placed on 22mm diameter x 0.5mm polished barium fluoride (BaF₂) windows (Crystan Limited, UK). The microscope video camera was used to image the cortical diaphysis (1.5 mm from the base of the growth plate), at the same location used for histomorphometric measurements of periosteal mineral apposition (Fig 5A). This location is ideal for assessing mineral apposition on a formation surface, without any prior remodelling because mouse bone lacks haversian systems ⁷⁸. sFTIRM mapping was performed with the synchrotron source, using a 15 x 15 µm aperture, represented by the 3 regions within the cortex. Spectra were collected from these 3 regions which

progressed perpendicularly into the cortex with the first positioned at the periosteal edge (Fig 5A). Spectra were collected in the mid-IR region from 750 cm⁻¹ to 3850 cm⁻¹ using a narrowband mercury cadmium telluride detector, at 8 cm⁻¹ spectral resolution and 128 co-added scans per pixel spectral resolution in transmission mode. A matching background spectrum was collected through clear BaF2. For each sample MMA reference spectra were collected from within the embedding material. All data acquisition was undertaken with Bruker OPUS version 6.5 and data analysis completed with OPUS version 7.2.

After acquisition, raw spectra for each region and sample were baseline corrected using a 3-point baseline at 1800, 1200 and 800 cm⁻¹. Residual MMA absorbance peaks were then subtracted using the relevant MMA reference spectrum for each sample by iterative manual subtraction. A residual 1730 cm⁻¹ MMA band remained after MMA subtraction which was not used for analysis. Spectroscopic parameters calculated were integrated peaks areas of the following bands: Phosphate (1180-916 cm⁻¹), amide I (1588-1712 cm⁻¹) and II (1600-1500 cm⁻¹), carbonate (890-852 cm⁻¹), Ratios were calculated as follows: mineral:matrix ratio (1180-916cm⁻¹/588-1712 cm⁻¹), carbonate:phosphate ratio (1180-916cm⁻¹/890-852 cm⁻¹) ratio and amide I:II ratio (1588-1712 cm⁻¹/1600-1500 cm⁻¹) ^{79,80}. Collagen crosslinking was determined by spectral curve fitting of the amide I and amide II peaks using Grams/AI (Version 9.2, Thermo Scientific, USA). The second-derivative of each peak was used to estimate subpeak positions at approximately 1660cm⁻¹ and 1690cm⁻¹, as previously described ¹⁷.

pFTIRI was applied to the same 3µm tibial sections at the same cortical diaphyseal region of analysis used for sFTIRM. This time, larger regions were imaged using a 340 x 340µm aperture either side of the 1500 µm mid-point. Tissue sections were scanned using a Hyperion 3000 spectral imaging system equipped with a Vertex-70 spectrometer (Bruker, Germany), a liquid-N2 cooled focal plane array (FPA: 128x128 elements; 40x40 microns each) detector and a Globar source. The FPA detector was continuously maintained at liquid-N2 temperature by an automated refilling system (Norhof LN2-cooling system #606; Maarssen, Netherland). The microscope and spectrometer were also continuously N2-purged and an insulation box protected the sample stage from ambient air. For all FTIR image acquisitions, a 15x magnification level and condenser were used. High-resolution FTIR images were obtained for microscopic analysis of tissue sections; 200 scans and an 8 cm⁻¹ spectral resolution was used for image acquisitions (140 ms FPA detector exposure per scan; spectral range = 3800-900 cm⁻¹). All FTIR images had an individual pixel dimension of 2.6x2.6 μ m, thus at $\sim \lambda/2$ for the mid-IR spectral interval. All infrared images were obtained in transmission mode. The images were obtained from subroutines of the Opus 7.5 software (Bruker-Optics, France). To quantitate region specific changes in amide I:II, the diaphyseal cortex was divided into thirds to obtain images of periosteal, intracortical and endosteal regions of interest. Images were quantitated using CytoSpec 1.4.0.3 (Bruker) and average spectra were extracted from each region, baselined and MMA-subtracted (similar to above). Integrations for the amide I and II peaks were calculated as follows: amide I (1590-1730 cm⁻¹) 28 and amide II (921-1190 cm⁻¹). We interpreted the amide I:II ratio as peptide bond vibrations of the collagen molecule. The amide I (C=O stretch) and amide II (C-N, N-H bend) molecular vibrations exhibit dichroism perpendicular (*z*-axis direction) and parallel (*x*-axis) to the collagen molecular triple helix axis, respectively ^{18,41}. The FTIR microscope was coupled with two polarising filters to measure molecular orientation of collagen fibres relative to the plane of the tissue section. The 0° polarising filter was used to measure bonds "in plane" (parallel to the section). The 90° polarising filter was used to measure bonds "out of plane" (perpendicular to the section). This allowed quantification of collagen fibres aligned in different directions through the diaphyseal cortex.

Hydroxyproline assay in hydrolysed bone samples

Following mechanical testing, all fragments of the broken femora were flushed of marrow, hydrolyzed and used for hydroxyproline assay to measure collagen content (31). Femoral samples were cut with scissors at the mid-diaphysis and the distal half of the femur flushed of marrow. The bone was weighed before and after dehydration in a 37°C incubator for one hour. Each sample was hydrolyzed by incubation overnight at 120°C in 1mL of 5M HCl per 20mg of bone. 50µl of each sample was used, and 6 serial dilutions of the hydroxyproline standard (1mg/mL) were used to generate a standard curve. 50µl of Chloramine T (Sigma-Aldrich) was added to each reaction and incubated at room temperature for 25 minutes. 500µl of Ehrlich's Reagent (Dimethyl-amino-benzaldehyde (Sigma-Aldrich), *n*-propanol

(99%, Sigma-Aldrich), perchloric acid (70%, AnalAR)) was added to each reaction and incubated at 65°C for 10 minutes (or longer if colour was not well developed). 100μl of each reaction was pipetted into a 96 well plate and absorbance measured using a POLARstar plate reader at 550nm and interpolated on the standard curve ⁸¹.

RNA sequencing

RNA samples were collected from flushed femora of 12 -week old female *Dmp1Cre.Efnb2^{f/f}* and cousin-bred control mice. Samples were collected on two occasions: on day 1, two *Dmp1Cre.efnB2^{f/f}* and three control samples were collected, while on day 2, one sample of each genotype was collected. Bones were snap frozn in liquid nitrogen, homogenized in OIAzol lysis reagent with a Polytron PTA 20S homogenizer at 4C prior to RNA extraction with a RNeasy Lipid Minikit (QIAgen). RNA sequencing was conducted on an Illumina HiSeq at the Australian Genome Research Facility to produce 100bp paired-end reads. Reads were mapped to the mouse genome (mm10) using Rsubread⁸². Read counts were obtained using featureCounts and Rsubread's inbuilt mm10 annotation ⁸³. Gene annotation was obtained from the NCBI gene information file downloaded 4 October 2016. Statistical analysis used the limma software package ⁸⁴. Genes were retained in the analysis if they achieved at least 0.65 read counts per million (cpm) in at least 3 samples. Immunoglobulin gene segments, ribosomal genes, predicted and pseudo genes, sex-linked genes (Y chromosome and Xist) and obsolete Entrez Gene IDs were filtered out. Quantile normalization was applied and read counts were transformed to log2-counts-per-million. Linear models were used to test for expression differences between deficient vs. control samples. The day of sample collection was included in the linear model as a blocking factor. Empirical sample quality weights were estimated ⁸⁵. Differential expression between the genotypes was assessed using empirical Bayes moderated t-statistics allowing for an abundance trend in the standard errors and for robust estimation of the Bayesian hyperparameters ⁸⁶. The Benjamini and Hochberg method was used to adjust the p-values so as to control the false discovery rate.

shRNA knockdown of ephrinB2 in Ocy454 cells

Two shRNA constructs were used to knock down ephrinB2: shRNA 1 (5' -CGG-GTG-TTA-CAG-TAG-CCT-TAT- 3') and shRNA 2 (5'-CAG-ATT-GTG-TAC-ATA-GAG-CAA-T-3'), both obtained from Sigma-Aldrich (St. Louis, MO, USA). shRNA were cloned into the PLKO lentiviral vector, as previously reported ⁹ and infected by retrovirus into undifferentiated Ocy454 cells. Infected cells were selected with puromycin (5µg/mL) and cultured at permissive temperature (33°C) before transfer to 37°C for differentiation. Knockdown was validated by quantitative real-time PCR (qRT-PCR).

Western blot analysis of chloroquine-treated Ocy454 cells

To test the level of autophagy in osteocytes lacking *Efnb2*, Ocy454 cells with *Efnb2* shRNA knockdown and vector controls were differentiated for 11 days and treated with chloroquine (40 μ m), a lysosomal degradation inhibitor, for 4 hours. Treated and untreated cells were then washed with phosphate-buffered saline (PBS) and

lysed in 50 mM Tris, pH 7.4, 150 mM NaCl, 10% glycerol, 1 mM EDTA, 1 mM EGTA, 0.1% NaPyroP, 1% Triton-X-100, Roche protease inhibitor. Samples were electrophoresed by 6% SDS-PAGE and transferred to Immobilon FL polyvinylidineflouride membrane (Millipore). Membranes were blotted with antibodies raised against LC3B (D11, Cell Signaling Technology, 3868), followed by incubation with anti-rabbit IgG 2° antibody fluorescently labelled with IR680 (LI-COR Biosciences). Immunoblots were visualised on an Odyssey membrane imaging system (LI-COR Biosciences) and the LC3II:I ratio was quantitated as the fold change of chloroquinetreated samples relative to untreated samples.

Statistics

All graphs show mean \pm SEM; number of samples (n) is reported in the figure legends. Statistical significance was determined by unpaired Student's t-tests for histomorphometric, mechanical and microCT analysis, and two-way ANOVA with Fisher's LSD test for sFTIRM-derived data (GraphPad Prism 6 (version 6.05)). p<0.05 was considered statistically significant.

References

- 1 Buenzli, P. R. & Sims, N. A. Quantifying the osteocyte network in the human skeleton. *Bone* **75**, 144-150, doi:10.1016/j.bone.2015.02.016 (2015).
- 2 Schaffler, M. B., Cheung, W. Y., Majeska, R. & Kennedy, O. Osteocytes: master orchestrators of bone. *Calcified tissue international* **94**, 5-24, doi:10.1007/s00223-013-9790-y (2014).
- Walker, E. C. *et al.* Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice. *J Clin Invest* **120**, 582-592, doi:10.1172/JCI40568 (2010).
- 4 Poole, K. E. *et al.* Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. *FASEB J* **19**, 1842-1844, doi:10.1096/fj.05-4221fje (2005).
- 5 Houston, B., Stewart, A. J. & Farquharson, C. PHOSPHO1-A novel phosphatase specifically expressed at sites of mineralisation in bone and cartilage. *Bone* **34**, 629-637, doi:10.1016/j.bone.2003.12.023 (2004).
- 6 Ling, Y. *et al.* DMP1 depletion decreases bone mineralization in vivo: an FTIR imaging analysis. *J Bone Miner Res* **20**, 2169-2177, doi:10.1359/JBMR.050815 (2005).
- Gowen, L. C. *et al.* Targeted disruption of the osteoblast/osteocyte factor 45 gene (OF45) results in increased bone formation and bone mass. *J Biol Chem* 278, 1998-2007, doi:10.1074/jbc.M203250200 (2003).
- 8 Miao, D. *et al.* Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1-34. *J Clin Invest* **115**, 2402-2411 (2005).
- 9 Ansari, N. *et al.* Autocrine and Paracrine Regulation of the Murine Skeleton by Osteocyte-Derived Parathyroid Hormone-Related Protein. *J Bone Miner Res*, doi:10.1002/jbmr.3291 (2017).
- 10 Lindsay, R. *et al.* Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium. *J Bone Miner Res* **22**, 495-502, doi:10.1359/jbmr.070104 (2007).
- 11 Miller, P. D. *et al.* Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial. *JAMA* **316**, 722-733, doi:10.1001/jama.2016.11136 (2016).
- 12 Allan, E. H. *et al.* EphrinB2 regulation by PTH and PTHrP revealed by molecular profiling in differentiating osteoblasts. *J Bone Miner Res* 23, 1170-1181, doi:10.1359/jbmr.080324 (2008).
- 13 Takyar, F. M. *et al.* EphrinB2/EphB4 inhibition in the osteoblast lineage modifies the anabolic response to parathyroid hormone. *J Bone Miner Res* **28**, 912-925, doi:10.1002/jbmr.1820 (2013).
- 14 Tonna, S. *et al.* EphrinB2 signaling in osteoblasts promotes bone mineralization by preventing apoptosis. *FASEB J* **28**, 4482-4496, doi:10.1096/fj.14-254300 (2014).

- 15 Sims, N. A. & Vrahnas, C. Regulation of cortical and trabecular bone mass by communication between osteoblasts, osteocytes and osteoclasts. *Arch Biochem Biophys* **561**, 22-28, doi:10.1016/j.abb.2014.05.015 (2014).
- 16 Martin, T. J. *et al.* Communication between ephrinB2 and EphB4 within the osteoblast lineage. *Advances in experimental medicine and biology* **658**, 51-60, doi:10.1007/978-1-4419-1050-9_6 (2010).
- 17 Vrahnas, C. *et al.* Anabolic action of parathyroid hormone (PTH) does not compromise bone matrix mineral composition or maturation. *Bone* **93**, 146-154, doi:10.1016/j.bone.2016.09.022 (2016).
- 18 Bi, X., Li, G., Doty, S. B. & Camacho, N. P. A novel method for determination of collagen orientation in cartilage by Fourier transform infrared imaging spectroscopy (FT-IRIS). *Osteoarthritis and cartilage* **13**, 1050-1058, doi:10.1016/j.joca.2005.07.008 (2005).
- 19 Khaminets, A. *et al.* Regulation of endoplasmic reticulum turnover by selective autophagy. *Nature* **522**, 354-358, doi:10.1038/nature14498 (2015).
- 20 Sandri, M. *et al.* Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. *Cell* **117**, 399-412 (2004).
- 21 Zaglia, T. *et al.* Atrogin-1 deficiency promotes cardiomyopathy and premature death via impaired autophagy. *J Clin Invest* **124**, 2410-2424, doi:10.1172/JCI66339 (2014).
- Carmignac, V. *et al.* Autophagy is increased in laminin α2 chain-deficient muscle and its inhibition improves muscle morphology in a mouse model of MDC1A. *Human Molecular Genetics* 20, 4891-4902, doi:10.1093/hmg/ddr427 (2011).
- 23 Bellot, G. *et al.* Hypoxia-induced autophagy is mediated through hypoxiainducible factor induction of BNIP3 and BNIP3L via their BH3 domains. *Molecular and cellular biology* **29**, 2570-2581, doi:10.1128/MCB.00166-09 (2009).
- 24 Hanna, R. A. *et al.* Microtubule-associated protein 1 light chain 3 (LC3) interacts with Bnip3 protein to selectively remove endoplasmic reticulum and mitochondria via autophagy. *J Biol Chem* **287**, 19094-19104, doi:10.1074/jbc.M111.322933 (2012).
- 25 Nascimbeni, A. C., Fanin, M., Masiero, E., Angelini, C. & Sandri, M. Impaired autophagy contributes to muscle atrophy in glycogen storage disease type II patients. *Autophagy* **8**, 1697-1700, doi:10.4161/auto.21691 (2012).
- 26 Buraschi, S. *et al.* Decorin causes autophagy in endothelial cells via Peg3. *Proceedings of the National Academy of Sciences of the United States of America* **110**, E2582-2591, doi:10.1073/pnas.1305732110 (2013).
- 27 Schoenherr, C. *et al.* Eps8 controls Src- and FAK-dependent phenotypes in squamous carcinoma cells. *J Cell Sci* **127**, 5303-5316, doi:10.1242/jcs.157560 (2014).
- 28 Magor, G. W. *et al.* KLF1-null neonates display hydrops fetalis and a deranged erythroid transcriptome. *Blood* **125**, 2405-2417, doi:10.1182/blood-2014-08-590968 (2015).

- 29 Hachez, C. *et al.* The Arabidopsis abiotic stress-induced TSPO-related protein reduces cell-surface expression of the aquaporin PIP2;7 through proteinprotein interactions and autophagic degradation. *The Plant cell* **26**, 4974-4990, doi:10.1105/tpc.114.134080 (2014).
- 30 Plissonnier, M. L. *et al.* Reciprocal antagonism between the netrin-1 receptor uncoordinated-phenotype-5A (UNC5A) and the hepatitis C virus. *Oncogene*, doi:10.1038/onc.2017.271 (2017).
- 31 Fedorko, M. Effect of chloroquine on morphology of cytoplasmic granules in maturing human leukocytes--an ultrastructural study. *J Clin Invest* **46**, 1932-1942, doi:10.1172/JCI105683 (1967).
- 32 Fuchs, R. K. *et al.* In situ examination of the time-course for secondary mineralization of Haversian bone using synchrotron Fourier transform infrared microspectroscopy. *Matrix Biol* **27**, 34-41, doi:10.1016/j.matbio.2007.07.006 (2008).
- 33 Donnelly, E., Boskey, A. L., Baker, S. P. & van der Meulen, M. C. Effects of tissue age on bone tissue material composition and nanomechanical properties in the rat cortex. *Journal of biomedical materials research. Part A* **92**, 1048-1056, doi:10.1002/jbm.a.32442 (2010).
- 34 Gourion-Arsiquaud, S. *et al.* Spatial variation in osteonal bone properties relative to tissue and animal age. *J Bone Miner Res* **24**, 1271-1281, doi:10.1359/jbmr.090201 (2009).
- 35 Paschalis, E. P. *et al.* FTIR microspectroscopic analysis of human osteonal bone. *Calcified tissue international* **59**, 480-487 (1996).
- 36 Paschalis, E. P., Betts, F., DiCarlo, E., Mendelsohn, R. & Boskey, A. L. FTIR microspectroscopic analysis of normal human cortical and trabecular bone. *Calcified tissue international* **61**, 480-486 (1997).
- 37 Rey, C., Renugopalakrishnan, V., Collins, B. & Glimcher, M. J. Fourier transform infrared spectroscopic study of the carbonate ions in bone mineral during aging. *Calcified tissue international* **49**, 251-258 (1991).
- 38 Legros, R., Balmain, N. & Bonel, G. Age-related changes in mineral of rat and bovine cortical bone. *Calcified tissue international* **41**, 137-144 (1987).
- 39 Akkus, O., Adar, F. & Schaffler, M. B. Age-related changes in physicochemical properties of mineral crystals are related to impaired mechanical function of cortical bone. *Bone* **34**, 443-453, doi:10.1016/j.bone.2003.11.003 (2004).
- 40 Rey, C., Collins, B., Goehl, T., Dickson, I. R. & Glimcher, M. J. The carbonate environment in bone mineral: a resolution-enhanced Fourier Transform Infrared Spectroscopy Study. *Calcified tissue international* **45**, 157-164 (1989).
- 41 Gadaleta, S. J., Landis, W. J., Boskey, A. L. & Mendelsohn, R. Polarized FT-IR microscopy of calcified turkey leg tendon. *Connect Tissue Res* **34**, 203-211 (1996).
- 42 Fraser, R. & MacRae, T. Conformation in Fibrous Proteins and Related Synthetic Polypeptides. (Academic Press, 1973).
- 43 Lu, Y. *et al.* DMP1-targeted Cre expression in odontoblasts and osteocytes. *Journal of dental research* **86**, 320-325 (2007).

- 44 Toyosawa, S. *et al.* Dentin matrix protein 1 is predominantly expressed in chicken and rat osteocytes but not in osteoblasts. *J Bone Miner Res* **16**, 2017-2026, doi:10.1359/jbmr.2001.16.11.2017 (2001).
- 45 Gadeleta, S. J. *et al.* A physical, chemical, and mechanical study of lumbar vertebrae from normal, ovariectomized, and nandrolone decanoate-treated cynomolgus monkeys (Macaca fascicularis). *Bone* **27**, 541-550 (2000).
- 46 McCreadie, B. R. *et al.* Bone tissue compositional differences in women with and without osteoporotic fracture. *Bone* **39**, 1190-1195, doi:10.1016/j.bone.2006.06.008 (2006).
- 47 Lloyd, A. A. *et al.* Atypical fracture with long-term bisphosphonate therapy is associated with altered cortical composition and reduced fracture resistance. *Proceedings of the National Academy of Sciences of the United States of America* **114**, 8722-8727, doi:10.1073/pnas.1704460114 (2017).
- 48 Lietman, C. D. *et al.* A transgenic mouse model of OI type V supports a neomorphic mechanism of the IFITM5 mutation. *J Bone Miner Res* **30**, 489-498, doi:10.1002/jbmr.2363 (2015).
- 49 Fratzl-Zelman, N. *et al.* Bone matrix hypermineralization in prolyl-3 hydroxylase 1 deficient mice. *Bone* **85**, 15-22, doi:10.1016/j.bone.2016.01.018 (2016).
- 50 Ansari, N. *et al.* Autocrine and Paracrine Regulation of the Murine Skeleton by Osteocyte-Derived Parathyroid Hormone-Related Protein. *J Bone Miner Res* **33**, 137-153, doi:10.1002/jbmr.3291 (2018).
- 51 Levine, B. & Kroemer, G. Autophagy in the pathogenesis of disease. *Cell* **132**, 27-42, doi:10.1016/j.cell.2007.12.018 (2008).
- 52 Mizushima, N. & Komatsu, M. Autophagy: renovation of cells and tissues. *Cell* **147**, 728-741, doi:10.1016/j.cell.2011.10.026 (2011).
- 53 Ponpuak, M. *et al.* Secretory autophagy. *Curr Opin Cell Biol* **35**, 106-116, doi:10.1016/j.ceb.2015.04.016 (2015).
- Nollet, M. *et al.* Autophagy in osteoblasts is involved in mineralization and bone homeostasis. *Autophagy* 10, 1965-1977, doi:10.4161/auto.36182 (2014).
- 55 Onal, M. *et al.* Suppression of autophagy in osteocytes mimics skeletal aging. *J Biol Chem* **288**, 17432-17440, doi:10.1074/jbc.M112.444190 (2013).
- 56 Piemontese, M. *et al.* Low bone mass and changes in the osteocyte network in mice lacking autophagy in the osteoblast lineage. *Sci Rep* **6**, 24262, doi:10.1038/srep24262 (2016).
- 57 Shapiro, I. M., Layfield, R., Lotz, M., Settembre, C. & Whitehouse, C. Boning up on autophagy: the role of autophagy in skeletal biology. *Autophagy* **10**, 7-19, doi:10.4161/auto.26679 (2014).
- Zahm, A. M., Bohensky, J., Adams, C. S., Shapiro, I. M. & Srinivas, V. Bone cell autophagy is regulated by environmental factors. *Cells Tissues Organs* 194, 274-278, doi:10.1159/000324647 (2011).
- 59 Anderson, H. C. Molecular biology of matrix vesicles. *Clin Orthop Relat Res*, 266-280 (1995).

- 60 Hoshi, K. & Ozawa, H. Matrix vesicle calcification in bones of adult rats. *Calcified tissue international* **66**, 430-434 (2000).
- 61 Rohde, M. & Mayer, H. Exocytotic process as a novel model for mineralization by osteoblasts in vitro and in vivo determined by electron microscopic analysis. *Calcified tissue international* **80**, 323-336, doi:10.1007/s00223-007-9013-5 (2007).
- 62 Mahamid, J. *et al.* Bone mineralization proceeds through intracellular calcium phosphate loaded vesicles: a cryo-electron microscopy study. *J Struct Biol* **174**, 527-535, doi:10.1016/j.jsb.2011.03.014 (2011).
- 63 Stanford, C. M., Jacobson, P. A., Eanes, E. D., Lembke, L. A. & Midura, R. J. Rapidly forming apatitic mineral in an osteoblastic cell line (UMR 106-01 BSP). *J Biol Chem* **270**, 9420-9428 (1995).
- 64 Qing, H. *et al.* Demonstration of osteocytic perilacunar/canalicular remodeling in mice during lactation. *J Bone Miner Res* **27**, 1018-1029, doi:10.1002/jbmr.1567 (2012).
- 65 Zambonin Zallone, A., Teti, A., Primavera, M. V. & Pace, G. Mature osteocytes behaviour in a repletion period: the occurrence of osteoplastic activity. *Basic Appl Histochem* **27**, 191-204 (1983).
- 66 Arthur, A., Koblar, S., Shi, S. & Gronthos, S. Eph/ephrinB mediate dental pulp stem cell mobilization and function. *Journal of dental research* **88**, 829-834, doi:10.1177/0022034509342363 (2009).
- 67 Heng, B. C. *et al.* EphrinB2 signaling enhances osteogenic/odontogenic differentiation of human dental pulp stem cells. *Arch Oral Biol* **87**, 62-71, doi:10.1016/j.archoralbio.2017.12.014 (2017).
- 68 Genet, F. *et al.* Neurological heterotopic ossification following spinal cord injury is triggered by macrophage-mediated inflammation in muscle. *J Pathol* **236**, 229-240, doi:10.1002/path.4519 (2015).
- 69 Mehrotra, R. Disordered mineral metabolism and vascular calcification in nondialyzed chronic kidney disease patients. *J Ren Nutr* **16**, 100-118, doi:10.1053/j.jrn.2006.01.006 (2006).
- 70 Yiu, A. J., Callaghan, D., Sultana, R. & Bandyopadhyay, B. C. Vascular Calcification and Stone Disease: A New Look towards the Mechanism. *J Cardiovasc Dev Dis* **2**, 141-164, doi:10.3390/jcdd2030141 (2015).
- 71 Spatz, J. M. *et al.* The Wnt Inhibitor Sclerostin Is Up-regulated by Mechanical Unloading in Osteocytes in Vitro. *Journal of Biological Chemistry* **290**, 16744-16758, doi:10.1074/jbc.M114.628313 (2015).
- 72 Gerety, S. S., Wang, H. U., Chen, Z. F. & Anderson, D. J. Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development. *Molecular cell* **4**, 403-414 (1999).
- 73 Kalajzic, I. *et al.* Dentin matrix protein 1 expression during osteoblastic differentiation, generation of an osteocyte GFP-transgene. *Bone* **35**, 74-82, doi:10.1016/j.bone.2004.03.006 (2004).
- 74 Johnson, R. W. *et al.* The primary function of gp130 signaling in osteoblasts is to maintain bone formation and strength, rather than promote osteoclast formation. *J Bone Miner Res* **29**, 1492-1505, doi:10.1002/jbmr.2159 (2014).

- 75 Chia, L. Y., Walsh, N. C., Martin, T. J. & Sims, N. A. Isolation and gene expression of haematopoietic-cell-free preparations of highly purified murine osteocytes. *Bone* **72**, 34-42, doi:10.1016/j.bone.2014.11.005 (2015).
- 76 Diez-Perez, A. *et al.* Microindentation for in vivo measurement of bone tissue mechanical properties in humans. *J Bone Miner Res* **25**, 1877-1885, doi:10.1002/jbmr.73 (2010).
- 77 Standal, T. *et al.* gp130 in late osteoblasts and osteocytes is required for PTHinduced osteoblast differentiation. *The Journal of endocrinology* **223**, 181-190, doi:10.1530/JOE-14-0424 (2014).
- 78 Parfitt, A. M. Osteonal and hemi-osteonal remodeling: the spatial and temporal framework for signal traffic in adult human bone. *Journal of cellular biochemistry* **55**, 273-286, doi:10.1002/jcb.240550303 (1994).
- 79 Boskey, A. L., Moore, D. J., Amling, M., Canalis, E. & Delany, A. M. Infrared analysis of the mineral and matrix in bones of osteonectin-null mice and their wildtype controls. *J Bone Miner Res* **18**, 1005-1011, doi:10.1359/jbmr.2003.18.6.1005 (2003).
- 80 Boskey, A. & Pleshko Camacho, N. FT-IR imaging of native and tissueengineered bone and cartilage. *Biomaterials* **28**, 2465-2478, doi:10.1016/j.biomaterials.2006.11.043 (2007).
- 81 Reddy, G. K. & Enwemeka, C. S. A simplified method for the analysis of hydroxyproline in biological tissues. *Clin Biochem* **29**, 225-229 (1996).
- 82 Liao, Y., Smyth, G. K. & Shi, W. The Subread aligner: fast, accurate and scalable read mapping by seed-and-vote. *Nucleic Acids Res* 41, e108, doi:10.1093/nar/gkt214 (2013).
- Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. *Bioinformatics* 30, 923-930, doi:10.1093/bioinformatics/btt656 (2014).
- 84 Ritchie, M. E. *et al.* limma powers differential expression analyses for RNAsequencing and microarray studies. *Nucleic Acids Res* **43**, e47, doi:10.1093/nar/gkv007 (2015).
- Ritchie, M. E. *et al.* Empirical array quality weights in the analysis of microarray data. *BMC Bioinformatics* 7, 261, doi:10.1186/1471-2105-7-261 (2006).
- Phipson, B., Lee, S., Majewski, I. J., Alexander, W. S. & Smyth, G. K. Robust Hyperparameter Estimation Protects against Hypervariable Genes and Improves Power to Detect Differential Expression. *Ann Appl Stat* 10, 946-963, doi:10.1214/16-A0AS920 (2016).

Acknowledgements

The authors thank the staff of the St. Vincent's Health Bioresources Centre for excellent animal care and assistance, Mr Joshua Johnson and Mrs Ingrid Poulton for technical assistance with histology, Dr Roger Curtain (Bio21) for technical assistance with BSEM, Dr Paul Roschger for advice on BSEM analysis and Dr Eleftherios Paschalis for advice on collagen crosslinking analysis. This work was supported by NHMRC Grants 1042129 and 1081242 to NAS and TJM, Program Grant 1054618 to GKS, the Australian and New Zealand Bone and Mineral Society Christine and TJ Martin Travel Award to CV, and a Brockhoff Foundation Grant to CV. JSO was supported by an ARC Future Fellowship. NAS was supported by an NHMRC Senior Research Fellowship. St. Vincent's Institute acknowledges the support of the Victorian State Government OIS program. Part of this work was untaken at the Infrared Microspectroscopy Beamline at the Australian Synchrotron, part of ANSTO.

Author contributions

Conceptualization, C.V., T.J.M. and N.A.S.; Investigation, C.V., T.A.D., N.A., B.C.I., H.N., Y.H., M.I., G.K.S., N.A.S.; Data curation, C.V., Y.H., G.K.S.; Analysis, C.V., T.A.D., N.A., C.P., Y.H.; Writing – Original Draft, C.V., N.A.S.; Writing- Review & Editing, all authors; Visualization, C.V., N.A.S.; Supervision, N.A.S.; Funding acquisition, N.A.S.

Declaration of Interests

The authors declare no competing interests.

Figure Legends

Figure 1: *Efnb2* is upregulated by PTH and PTHrP in osteocyte-like cells and confirmation of ephrinB2 knockdown in *Dmp1Cre.EfnB2^{f/f}* osteocytes. A,B: *Efnb2* mRNA levels, relative to *Hprt1*, in Ocy454 cells differentiated for 14 days and treated with 10nM hPTH(1-34) or hPTHrP(1-141) for 6h (A) and Ocy454 cells with stable shRNA knockdown of PTHrP (*Pthlh*) at 0, 7 and 14 days of differentiation (B). Data are mean ± SEM, n=6 replicates; representative of 3 independent experiments. C: *Efnb2* mRNA levels in GFP+ osteocytes isolated from *Dmp1Cre.DMP1-GFP-Tg.Efnb2^{w/w}* (w/w) and *Dmp1Cre.DMP1-GFP-Tg.Efnb2^{f/f}* (f/f) mice compared to GFP-cells. N.D. = not detected. Data mean ± SEM of 2 experiments, n= 6 mice/group; pooled. **p<0.05*, ***p<0.01*, ****p<0.001* compared to control by Student's t-test.

Figure 2: 12-week-old female *Dmp1Cre.EfnB2f/f* (f/f) mice have impaired femoral strength compared to *Dmp1Cre* controls (w/w). A: Average Load-Deformation curve from 3 point bending tests (each dot represents the average load and deformation for the noted sample group; error bars excluded to highlight the shape of curves). B: Kaplan-Meier curve showing percentage of unbroken femora with increasing deformation (p<0.0008 based on Log-rank (Mantel-Cox) test). C-F: Calculated indices of bone strength: ultimate force (C), ultimate deformation (D), post-yield deformation (E) and energy absorbed to failure (F). Data are mean ± SEM, n = 10-12/group. *p<0.05, **p<0.01, ***p<0.001 vs w/w controls.

Figure 3: Impaired strength in *Dmp1Cre.Efnb2^{f/f}* **mice is a material defect. A:** Femoral moment of inertia. **B-E:** 3 point bending test data corrected for bone cross sectional area, including average stress-strain curve (each dot represents the 41 average load and deformation for the noted sample group; error bars excluded to highlight the shape of curves) (B), ultimate stress (C), ultimate strain (D), and toughness (E) of 12-week old female $Dmp1Cre.Efnb2^{w/w}$ (w/w) and $Dmp1Cre.Efnb2^{f/f}$ (f/f) femora. F: Indentation distance increase (IDI) derived from reference point indentation of femora. Data are represented as mean ± SEM, n = 10-12/group. *p<0.05, **p<0.01 vs w/w controls.

Figure 4: Elevated mineral accrual, carbonate deposition, and reduced amide I:II ratio in 12-week old female *Dmp1Cre.Efnb2^{f/f}* cortical bone. A: Regions of periosteal bone used for sFTIRM analysis. Note calcein label on the newly mineralized periosteum; regions 1-3 ($15\mu m^2$ in size) denote bone areas of increasing maturity with increasing distance from the periosteal edge. B: Averaged sFTIRM spectra from region 2 of all *Dmp1Cre.Efnb2^{w/w}* (w/w) and *Dmp1Cre.Efnb2^{f/f}* (f/f) tibiae; boxes show approximate regions of the Amide I, Amide II, Phosphate and Carbonate peaks. C-E: sFTIRM-derived mineral:matrix (C), carbonate:mineral (D), amide I:II (E) and collagen-crosslinking (F) ratios in regions 1-3 of w/w and f/f tibiae. Data are represented as mean ± SEM, n = 13/group. *p<0.05, **p<0.01, ***p<0.001 vs region 1 of same genotype (bone maturation effect), +p<0.05, **p<0.01 vs w/w in the same region (genotype effect).

Figure 5: Polarised FTIR imaging confirms altered collagen distribution in 12week old female *Dmp1Cre.Efnb2^{f/f}* mice. Representative FTIR images showing relative intensity of Amide I and Amide II peaks in the cortical midshaft from $Dmp1Cre.Efnb2^{w/w}$ (w/w) and $Dmp1Cre.Efnb2^{f/f}$ (f/f) mice under the (A,B) 0° and

42

(D,E) 90° polarising filters; quantification of the amide I:II ratio under the (C) 0° and (F) 90° polarising filter in periosteal, intracortical and endocortical regions; regions shown in the top left panel of A; p = periosteal region, c = central region, e = endocortical region. Data are represented as mean \pm SEM, n = 12-13/group. *p<0.05 vs *Dmp1Cre.Efnb2*^{w/w} at the same region (genotype effect), +p<0.05, ++p<0.01, +++p<0.001 vs region indicated by the bracket, within the same genotype (region effect).

Figure 6. RNA sequencing from marrow-flushed femora of 12-week old female *Dmp1Cre.Efnb2^{f/f}* mice show upregulation of autophagy-related genes, compared to controls. Panels (A) and (B) show the top 30 most differentially expressed genes in *Dmp1Cre.Efnb2^{f/f}* mice compared to controls, divided into upregulated (A) and down-regulated genes (B). Genes associated with autophagy are indicated by *. Columns give gene symbol, Entrez Gene ID, log2-fold-change, average log2-expression, moderated t-statistic, P-value and false discovery rate (FDR). C: *Efnb2* stable knockdown in Ocy454 cells differentiated for 7, 11 and 14 days, 6 replicates. D: Fold change of LC3-II:I ratio in *Efnb2* shRNA knockdown cells treated with chloroquine (CQ) for 4 hours compared to basal levels of each construct. Data are represented as mean \pm SEM, 3 replicates, *p<0.05 vs. vector control.

Figure 7. Model of how osteocytic ephrinB2 regulates bone matrix composition. (A) In control bone ($Dmp1Cre.Efnb2^{w/w}$) both osteoblasts and osteocytes express ephrinB2. Osteoblasts reside on the bone surface, and pass through a transition (dashed arrows) to become mature, matrix embedded osteocytes. The process of bone matrix maturation is shown on the right of each 43

panel, with the three measurement regions (1, 2, 3). Osteoblasts deposit collagencontaining osteoid (triple helical collagen fibres). In the first region of newly-formed bone, mineral deposition is initiated. Mineral crystals (yellow stars) and carbonte (orange circles) continue to accumulate, and collagen fibres become more compact as the matrix matures. (B) *Dmp1Cre.Efnb2*^{///} mice express ephrinB2 in osteoblasts, but not osteocytes. The transition of osteoblasts to osteocytes is increased resulting in increased osteocyte density, and osteocytes have increased levels of autophagic flux (green cells). Osteoid deposition occurs normally, and the initiation of mineralization commences at the same rate (red arrow), but as soon as it starts, mineral deposition occurs at a greater level in newly-formed bone (region 1) and in more mature bone regions (2, and 3) to reach a level where there is more mineral, more carbonate substitution and more compaction of collagen fibres compared to controls. Ultimately this leads to more brittle bone.

Table 1. Additional structural and material properties of 12-week old femaleDmp1Cre.Efnb2^{f/f} femoral cortical bone, compared to controls.

	Dmp1Cre.Efnb2 w/w	Dmp1Cre.Efnb2 ^{f/f}	
Structural properties			
Yield Force (N)	14.98 ± 0.63	11.15 ± 0.90 ^b	
Yield deformation (mm)	0.18 ± 0.01	0.12 ± 0.01 ^b	
Stiffness (N/mm)	139.32 ± 10.16	134.59 ± 10.31	
Anteroposterior (AP) width (mm)	1.24 ± 0.02	1.25 ± 0.02	
Mediolateral (ML) width (mm)	1.80 ± 0.03	1.75 ± 0.01	
Material properties			
Yield Stress (MPa)	31.96 ± 2.12	24.15 ± 1.81 ^a	
Yield Strain (%)	0.04 ± 0.002	0.02 ± 0.001^{b}	
Elastic Modulus (MPa)	1430.5 ± 105.8	1320.4 ± 93.5	
Additional data			
Periosteal Perimeter (µm)	6.90 ± 0.13	6.86 ± 0.07	
Marrow Area (mm²)	0.94 ± 0.04	0.97 ± 0.02	
Periosteal Mineral Appositional Rate			
(µm/day)	0.98 ± 0.12	1.07 ± 0.10	
Periosteal Mineralising Surface / Bone			
Surface (%)	88.41 ± 7.45	80.82 ± 6.30	
Cortical Tissue Mineral Density (g/cm³)	1.13 ± 0.02	1.13 ± 0.02	

Data are represented as mean ± SEM; n = 12/group

^ap < 0.05, ^bp < 0.01, versus *Dmp1Cre.Efnb2* ^{w/w} controls, Student's t-test.

Table 2. Histomorphometric analyses of trabecular bone in 12-week old female *Dmp1Cre.Efnb2^{f/f}* tibiae compared to sex and age-matched *Dmp1Cre.Efnb2^{w/w}* controls.

	Dmp1Cre.Efnb2 w/w	Dmp1Cre.Efnb2 ^{f/f}
Mineral Apposition Rate (µm/day)	2.09 ± 0.09	1.96 ± 0.10
Mineralising surface/Bone Surface (%)	34.51 ± 2.52	34.87 ± 1.04
Bone Formation Rate/Bone Surface		
(µm²/µm/day)	0.71 ± 0.04	0.68 ± 0.04
Osteoid Thickness (µm)	2.26 ± 0.17	2.66 ± 0.21
Osteoid Surface (%)	7.39 ± 1.45	9.83 ± 2.29
Osteoblast Surface (%)	13.60 ± 1.81	16.25 ± 2.20
Osteoclast Surface (%)	8.78 ± 1.25	11.58 ± 0.95


Data are represented as mean ± SEM; n = 7-11/group

Table 3. Collagen fibre deposition and osteocyte lacunar parameters in the femoral midshaft from 12-week old female $Dmp1Cre.Efnb2^{w/w}$ (w/w) and $Dmp1Cre.Efnb2^{f/f}$ (f/f) mice.


	Dmp1Cre.Efnb2 ^{w/w}	Dmp1Cre.Efnb2 ^{f/f}
Woven bone (% total bone)	17.00 ± 1.58	19.33 ± 2.30
Average osteocyte lacunar size (µm ²)	35.27 ± 1.09	35.76 ± 0.83
Osteocyte lacunar size - largest 20%	59.81 ± 2.05	60.11 ± 2.05
(µm²)		
Osteocyte lacunar density (/mm ²)	232.91 ± 12.27	268.75 ± 9.26 ^a
Whole bone hydroxyproline (µg/mg	36.38 ± 3.37	44.51 ± 2.87 ^a
protein)		


Data are represented as mean ± SEM; n = 10-12/group


^ap < 0.05 versus *Dmp1Cre.Efnb2* ^{*w/w*} controls, Student's t-test.




bioRxiv preprint doi: https://doi.org/10.1101/260711; this version posted March 1, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.



















D



















0.000


1 2 3 1 Regions

2 3




Ε






F




w/w

☐ f/f

certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.





Α


his Daireannaí		bi.org/10.1101/2	60 711	·		e e a construite de la construite a
Gene	Gene ID	Log2FC	Average Expression	Ĭ	P-value	FDR
Pira6	18729	1.788	2.245	10.52	3.19E-06	0.009485
Fam134b *	66270	1.907	6.821	10.51	3.22E-06	0.009485
Fbxo32 *	67731	2.443	7.223	10.33	3.71E-06	0.009485
Vldlr	22359	1.224	6.325	10.3	3.80E-06	0.009485
Abca8a	217258	1.116	5.984	9.99	4.84E-06	0.009761
Cnksr1	194231	1.246	3.741	9.71	6.07E-06	0.009761
Lama2 *	16773	1.475	6.078	9.37	8.05E-06	0.009761
Bnip3 *	12176	1.363	5.117	9.21	9.31E-06	0.009761
Slc7a2	11988	1.437	5.507	9.19	9.46E-06	0.009761
Trim63 *	433766	2.476	7.151	9.02	1.09E-05	0.010188
Cped1	214642	0.993	5.745	8.92	1.19E-05	0.010288
Klf9	16601	0.816	6.472	8.77	1.37E-05	0.010288
Zim1	22776	1.597	1.624	8.55	1.66E-05	0.010288
Peg3 *	18616	1.748	4.988	8.44	1.84E-05	0.010288
Abca6	76184	1.576	3.62	8.44	1.84E-05	0.010288
Slc15a2	57738	1.446	4.194	8.43	1.86E-05	0.010288
Myo15	17910	1.291	2.933	8.09	2.56E-05	0.011489


Β

Gene	Gene ID	Log2FC	Average Expression	Т	P-value	FDR
Ccdc92b	432582	-3.679	2.509	-17.73	4.23E-08	0.000634
BC049730	232972	-5.568	2.26	-11.2	1.92E-06	0.009485
Sec14l2	67815	-1.066	5.35	-9.69	6.20E-06	0.009761
2610507l01Rik	72203	-4.421	3.956	-9.56	6.88E-06	0.009761
Eps8l1 *	67425	-4.1	2.602	-9.47	7.41E-06	0.009761
Pirb	18733	-1.242	6.794	-9.15	9.78E-06	0.009761
Fam110c	104943	-3.115	0.935	-8.87	1.25E-05	0.010288
Klf1 *	16596	-1.095	7.14	-8.7	1.45E-05	0.010288
Abcg4	192663	-0.884	5.372	-8.49	1.76E-05	0.010288
Tspo2 *	70026	-1.1	5.864	-8.46	1.80E-05	0.010288
Unc5a *	107448	-1.321	3.183	-8.45	1.83E-05	0.010288
Sycp1	20957	-3.876	-0.345	-8.17	2.37E-05	0.011489
Unc5cl	76589	-1.527	2.332	-8.16	2.40E-05	0.011489

Vector

shRNA 1





for this preprint (which was not permission.

